Drug Trial Radar · NCT05485974
A Dose Escalation Study of HBI-2438 in Patients With Solid Tumors Harboring KRAS G12C Mutation
Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
44
Planned (sponsor's estimate)
Start
Aug 1, 2022
Primary completion
Dec 31, 2026
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- HUYABIO International, LLC.Industry
- Sponsor type
- Industry
- First posted
- Aug 3, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase 1 dose escalation study in patients with advanced solid tumors harboring KRAS G12C mutation to determine the maximum tolerated dose and recommended Phase II dose of HBI-2438 and characterize its pharmacokinetic profile.
Conditions
- Lung Cancer
- Non Small Cell Lung Cancer
- Colorectal Cancer
- Cancer of Pancreas
- Colon Cancer
- Solid Tumor
- Cancer
Interventions
HBI-2438Drug
KRAS G12C Inhibitor
Primary outcomes
What the sponsor says the trial is designed to measure.
- To determine the maximum tolerated dose (MTD)Time frame: Up to 36 months
- adverse events (AEs), and serious adverse events (SAEs) overallTime frame: Up to 36 months
Locations
14 sites in 2 countries. Site status is shown where the registry gives one.
California Cancer Associates for Research and Excellence, Inc. (cCare)
Encinitas, California
The Oncology Institute of Hope and Innovation
Glendale, California
The Oncology Institute of Hope and Innovation
Long Beach, California
The Oncology Institute of Hope and Innovation
Pasadena, California
California Cancer Associates for Research and Excellence, Inc. (cCare)
San Marcos, California
The Oncology Institute of Hope and Innovation
Santa Ana, California
Sarcoma Oncology
Santa Monica, California
Innovative Clinical Research Institute (ICRI)
Whittier, California
The Oncology Institute of Hope and Innovation
Whittier, California
BRCR Medical Center
Plantation, Florida
Michigan Center of Medical Research
Farmington Hills, Michigan
Alliance for Multispecialty Research, LLC
Kansas City, Missouri
Gabrail Cancer Center
Canton, Ohio
Pan American Center for Oncology Trials (PanOncology Trials)
Rio Piedras, Puerto Rico, Puerto Rico
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.